Background Mothers of preterm infants often struggle to produce enough breast milk to meet the nutritional needs of their infant. Galactagogues such as domperidone are often prescribed to increase breast milk supply but evidence supporting their role in clinical practice is uncertain.
Introduction
The maternal and infant benefits of breastfeeding are well recognised, with breast milk considered the optimal form of nutrition to support the growth and development of term and preterm infants. 1, 2 For preterm infants in NICU (Neonatal Intensive Care Unit), the feeding of mothers' own breast milk reduces the incidence, severity and risk of necrotising enterocolitis (NEC), late onset sepsis, chronic lung disease, retinopathy of prematurity, rehospitalisation after NICU discharge and neurodevelopmental problems in infancy and childhood. 3 Further, the ability of a mother to provide her own breast milk provides important psychological benefits, with breastfeeding mothers often reporting greater feelings of attachment, empowerment and confidence. 4 Mothers of preterm infants, however, face many challenges in initiating, establishing and maintaining an adequate supply of breast milk during their infant's prolonged hospitalisation. When insufficient milk supply persists despite the provision of appropriate lactation support, pharmacological treatment with a galactagogue (a medication that increases mother's milk supply) is often considered. 5 One of the beststudied and most commonly utilised galactagogues is domperidone, a dopamine receptor antagonist that is thought to increase breast milk supply by increasing serum prolactin levels. 6 Previous studies have demonstrated that use of domperidone is widespread [7] [8] [9] with a recent clinical practice survey from Australia and New Zealand identifying that domperidone is considered the first-line in the treatment of low milk supply in the Neonatal Unit setting. 10 Despite high frequency of use, controversy surrounds the use of domperidone, with key issues related to the regulatory status of domperidone.
11 Domperidone has been the subject of regulatory warnings due to concerns regarding its QTc interval prolongation effects, but the relevance of these findings to younger, healthier lactating women has been questioned. [12] [13] [14] A recent commentary concluded that data are too limited in quality and quantity to provide evidence of effectiveness of domperidone for lactation enhancement. 11 That commentary did not undertake a systematic review or conduct a meta-analysis to determine currently available evidence on efficacy and safety, with the most recent Cochrane review published in 2012 and limited to the inclusion of just two studies. 15 In light of this, we sought to undertake a systematic review and meta-analysis to evaluate the efficacy and safety of domperidone for treatment of low milk supply in mothers of preterm infants.
Methods

Data sources and search strategy
This review was performed and reported in accordance with the preferred reporting items in systematic review and meta-analysis (PRISMA). 16 We searched three electronic databases from inception to January 2017: Ovid MEDLINE, Embase and Web of Science. Medical subject headings (e.g. MeSH headings) and free word combinations using Boolean logic of the following search items were used: domperidone AND lactation, breastfeeding OR breast milk (Appendix S1). Previous reviews, bibliographies of published trials and cross-references were also searched. Further, we searched the Australian New Zealand Clinical Trials Registry and the US ClinicalTrials.gov register for unpublished and ongoing trials. No language restrictions were applied to the search.
Study selection and data extraction
We included all randomised controlled trials (RCTs) that compared the effects of domperidone with those of placebo for the treatment of low milk supply in mothers of preterm infants. Eligible studies were those involving mothers of preterm infants (<37 weeks' gestation) who were not able to supply sufficient breastmilk for their infants' nutritional requirements and randomisation occurred more than 72 hours following delivery. In addition, eligible studies where domperidone was prescribed for a minimum of 5 days following randomisation. The minimum duration of treatment was determined to be 5 days as this reflects the shortest duration of treatment identified in a recent clinical practice survey. 10 Studies published only as abstracts were eligible for inclusion providing there was sufficient information presented in the abstract to demonstrate that the study met the inclusion criteria. In the case of a study published only in short format (i.e. conference abstract 17 or letter to the editor 18 ), we contacted the study authors, who provided us with additional required data.
Two independent reviewers (L.G. and R.G.) screened the titles and abstracts of all studies initially identified, according to the selection criteria. Any disagreement was resolved through consensus or consultation with a third independent reviewer. Full texts were retrieved from studies that satisfied all selection criteria. Two reviewers (L.G. and L.S.) utilised a standardised data extraction sheet to extract the following data independently: study characteristics (authors, years of publication, country), patient characteristics (eligibility criteria) and treatment outcome measures. Any disagreement in extracted data was resolved through consensus or consultation with a third independent reviewer. The primary maternal outcome for which data were extracted was breast milk volume of EBM (in ml/day), which was either reported as change from baseline (mean difference, MD) or final value only. Where median breast milk volume was reported, as was the case for Rai et al., 18 this was converted to an estimated mean value using a previously validated approach. 19, 20 Where the standard deviation for change in breast milk volume was missing, as was the case for Campbell Yeo et al., 21 the standard deviation was imputed using the approach outlined by the Cochrane Handbook for Systematic Reviews of Interventions. 22 The secondary outcomes for which data were extracted included longer-term breastfeeding outcomes after completion of the RCT as well as maternal and neonatal adverse events reported during the RCT.
Study quality assessment
Two independent investigators (L.G. and L.S.) evaluated the methodological quality of included studies by assessing the risk of bias in accordance with the Cochrane collaboration tool. 23 In summary, risk of bias was assessed by answering questions related to the following aspects of studies with 'Yes' (low risk of bias), 'No' (high risk of bias) or 'Unclear' (lack of information or uncertainty over potential bias): random sequence generation, allocation concealment, blinding of participants, blinding of outcome assessment, incomplete outcome data, selective reporting and other bias. Any disagreement was resolved by consensus.
Data synthesis
We used Cochrane Review manager software (REVMAN version 5.3, The Nordic Cochrane Centre, Copenhagen, Denmark) for quantitative analysis. The mean differences (MD) in breast milk volume and associated 95% confidence intervals (CIs) were calculated using a fixed-effects model. The relative risk (RRs) of adverse events and associated 95% confidence intervals (CIs) were calculated using a fixed-effects model.
We planned to use a random effects model if significant clinical heterogeneity was evident. Statistical heterogeneity was assessed in each meta-analysis using the T 2 , I 2 and v 2 statistics. We regarded heterogeneity as substantial if T 2 > 0 and either I 2 was >30% or a Chi-squared test for heterogeneity resulted in P < 0.10. Heterogeneity was also visually explored using Forest plots to demonstrate MDs, RRs and relative 95% CIs for individual studies. We planned to investigate potential for reporting bias using funnel plots if more than ten studies were identified as eligible for inclusion in the meta-analysis. Data permitting, we planned to conduct additional analyses according to gestational age at birth (very preterm <32 weeks versus moderate to late preterm 32 to <37 weeks), postnatal age, duration of treatment and study quality. We performed subgroup analyses to investigate the potential sources of heterogeneity. With respect to study quality, based on the risk of bias evaluation within each of the seven domains as outlined in the Cochrane collaboration tool, we determined a study to be of high quality if it received a low risk score on at least four domains, with three mandatory domains being sequence generation, allocation concealment and incomplete outcome data. 22 Incomplete outcome data were considered critical to methodological quality given the potential to be related to the primary study outcome of breast milk volume. That is, women who withdrew from the study may be more likely to have had an insufficient response to the assigned treatment. Additionally, sensitivity analyses were conducted to assess the influence of each individual study on the pooled estimates and to evaluate whether the overall estimates were dominated by one single study. Figure 1 summarises the identification and selection process. Of the 232 studies identified after removal of duplicates, 10 full-text articles were screened for eligibility. Five of these were deemed ineligible owing to inclusion of mothers of term infants, 24, 25 or lack of placebo comparison group [26] [27] [28] (Appendix S2) . This left a total of five studies included in the systematic review and meta-analysis. 17, 18, 21, 29, 30 Details of the characteristics of the studies are outlined in Table S1 . A total of 210 women were enrolled in these trials and randomised to either domperidone or placebo groups. Outcome data were reported on 192 women, including 95 randomised to domperidone and 97 to placebo.
Results
Study characteristics
Inclusion criteria varied across studies. Gestational age ranged from <30 to <37 weeks. Low milk supply was variably defined as inability to attain a fixed volume of expressed breast milk (e.g. <250 ml/day), or inability to attain a volume of expressed breast milk relative to their infant's weight (e.g. <150 ml/kg/day) or total feed requirements (e.g. <100% of total daily requirements). All studies utilised a dose of 10 mg three times daily (30 mg/day), with a variable duration of treatment ranging from 5 to 14 days. In the study by Asztalos et al. 29 following an initial 14-day treatment with either domperidone or placebo, all women then received domperidone for another 14 days. Only data at the end of the initial 14-day treatment were included in this meta-analysis.
Quality assessment
Risk of bias assessments for individual studies is summarised in Table S2 , with a detailed description and justification of bias allocation outlined in Appendix S3. Overall, the methodological assessment of included studies was of good quality. The main area of possible bias related to incomplete outcome data, with attrition of more than 10% of participants occurring within the domperidone treatment arm of three studies (45%, 30 18% 17 and 12% 18 ), and the placebo arm of three studies (18% 17 and 11% 29, 30 ). Overall, three studies were identified as having high risk of bias related to missing data due to the potential for missing data significantly to influence the primary outcome. 17, 29, 30 Comparison results
All five studies provided data on the primary efficacy outcome of daily breast milk volume, reported as either change from baseline, 17, 18, 21, 30 or final value only. 29 Our meta-analysis identified that domperidone use leads to a modest increase in daily expressed breast milk volume compared with placebo (MD 88.3 ml/day; 95% CI 56.8-119.8 ml/day; Figure 2 ).
Longer-term breastfeeding outcomes were investigated in three studies but none was suitable for meta-analysis due to heterogeneity in evaluation timing or to a lack of sufficient data. 21, 29, 30 Further, following completion of each clinical trial, women were able to obtain and use domperidone in an unrestricted manner. With that in mind, da Silva et al. 30 reported no difference in the proportion of infants discharged home who were breastfeeding between the two groups; however, the proportions were not stated. Campbell-Yeo et al. reported on the proportion of women continuing to breastfeed in the domperidone and placebo groups at 2 weeks after the end of the study period (86.4 versus 62.5%; P = 0.13) and at infant discharge from hospital (54.6 versus 52.2%; P = 0.87). 21 Asztalos et al. also reported on the proportion of women breastfeeding in the domperidone and placebo groups, this time at term-corrected age (57.8 versus 60.0%; P = 0.83) and at 6 weeks' corrected age (42.2 versus 44.4%; P = 0.83). 29 Maternal adverse events were assessed in all included studies, although reporting of these differed among the studies. Three studies reported no significant maternal adverse events at all in either treatment group. 18, 21, 30 Adverse events were reported in two studies, 17, 29 with the pooled estimate identifying no difference in prevalence between women receiving domperidone compared with placebo (RR 1.05, 95% CI 0.65-1.71; Figure 3 ). Adverse events reported included headache, gastrointestinal symptoms, respiratory symptoms and neuro-behavioural symptoms (e.g. sleep disturbance, dizziness, drowsiness or restlessness). No serious adverse effects were reported in any study and no women withdrew from any study directly due to adverse effects. Potential cardiac adverse events were only specifically evaluated in one study. 29 Asztalos et al. investigated for potential prolonged QTc syndrome before and after intervention. 29 No women were identified as having a prolonged QTc interval.
Neonatal adverse events were only specifically reported in three studies. 21, 29, 30 No neonatal adverse events in either treatment group were reported in two studies. 21, 30 Asztalos et al. reported 14 adverse events in each treatment group but did not report on prevalence. 29 Further, they investigated potential prolonged QTc syndrome in 91 infants at the start of the study and 76 infants at the end. Five infants were found to have a QTc interval >500 ms, two at the start of the study and three at the end. None of these infants was clinically asymptomatic and no intervention was required.
Heterogeneity and sensitivity analyses
While some degree of heterogeneity was noted between studies, this was not considered to be important. A similar treatment effect was observed when studies were stratified according to duration of treatment of 5-7 days (MD 88.6 ml/day; 95% CI 52.1-125.2 ml/day) or 14 days (MD 87.4 ml/day; 95% CI 25.4-149.5 ml/day; Figure S1 ). A formal subgroup analysis identified no statistically significant difference according to duration of treatment (P = 0.97). When stratified according to study quality, difference in breast milk volume was greater among studies identified at low risk of bias (MD 121.7 ml/day; 95% CI 74.6-168.9 ml/day) compared with those identified at high risk of bias (MD 61.5 ml/day; 95% CI 19.2-103.8 ml/day; P interaction = 0.06, Figure S2 ). Additional sensitivity analyses were performed according to sequential omission of individual studies and evaluation of the overall impact on the pooled results. The omission of any individual study did not substantially alter the overall mean difference in maternal breast milk volume (Table S3) .
Discussion
Main findings
Our systematic review and meta-analysis demonstrates that in situations where mothers of preterm infants continue to experience low milk supply despite the use of non-pharmacological strategies, short-term domperidone use results in a moderate 86 ml/day increase in expressed breast milk volume. This increase represents almost 40% of total daily milk intake for a typical preterm infant weighing 1.5 kg and receiving enteral feeds of 150 ml/kg/day. The total sample included in the meta-analysis was <200 women; nonetheless, no maternal or neonatal adverse events from any RCT were attributed to domperidone.
Strengths and limitations
We made considerable efforts to include all relevant RCTs, which included contacting authors to obtain additional information. The validity of the results is further supported by the comprehensive literature search, independent study selection and data extraction processes, methodological quality assessment, and use of sensitivity analyses. Despite differences in duration of domperidone treatment across studies, there was a limited heterogeneity in the effectiveness measure. The observed benefit of domperidone remained following a range of sensitivity analyses, adding some robustness to the findings and suggesting that the results are not unduly influenced by extreme findings from one or two RCTs.
The most important limitation is the small number of included trials and small number of participants in each of these trials. By comparison, past meta-analyses included only two or three RCTs, 15, 31 and the recent publication of new RCTs on this topic indicate that this systematic review is both timely, with the most up-to-date data and the greatest number of RCTs. For the primary outcome of expressed breast milk volume these studies are reasonably well powered, but with only 105 women in total exposed to domperidone, the studies remain underpowered for identifying less common maternal or infant adverse outcomes.
Further, due to identifying fewer than ten studies for inclusion we were unable to explore publication bias. Nonetheless, the potential for publication bias appears somewhat mitigated by the fact that we did not identify any registered clinical trials involving domperidone that remain unpublished.
Lastly, this meta-analysis only studied the effect of domperidone in mothers of preterm infants and therefore cannot be used to determine its role in mothers of term infants.
Interpretation
The benefits of enhancing breast milk supply to maternal and infant wellbeing are established. Every 10 ml/kg/day increase in mothers' own milk fed to preterm infants was associated with~1-point higher scores on Bayley's Scale of Infant Development and a 5% reduction in odds of rehospitalisation by 2.5 years of age. 32 Thus, the additional 88 ml of mother's own milk supply following domperidone treatment may have a clinically meaningful impact on preterm health and development. Further, higher milk supply in the postpartum period is associated with improved longterm breastfeeding outcomes. 33 A recent randomised study by O'Connor et al. 34 demonstrated no difference in neurodevelopmental outcomes of very preterm infants fed supplemental donor human milk compared with preterm formula, highlighting the critical importance of strategies for enhancing mother's own milk production.
Given the myriad of factors contributing towards insufficient milk supply, domperidone use should not be considered a panacea for improving breastfeeding outcomes for all women. Non-pharmacological strategies such as breastfeeding education, early initiation of breastfeeding, promotion of kangaroo mother care, supply and appropriate use of breast pumps, and regular breast milk expression, remain paramount for supporting optimal breastfeeding outcomes. 35 Based on this meta-analysis, there is insufficient evidence to determine whether treatment effects differ according to dose or duration of treatment. Placebo controlled studies identified in this review are limited to those investigating a daily dose of 30 mg. Two studies have investigated the effects of a higher dose of domperidone (60 mg/day) on treatment response but were excluded from this review as they did not include a placebo group. 26, 27 Both these RCTs failed to demonstrate a statistically significant difference between treatment groups. 26, 27 Asztalos et al. observed an increase in breast milk volume from baseline to day 14, but no further increase was observed over the subsequent 14 days. 29 Given that no study has continued to observe women after cessation of treatment, it is uncertain whether continued use is required to sustain the observed increase in breast milk volume or whether supply remains unaffected. Further, the optimal approach towards treatment cessation remains unclear. Common practice recommendations for tapering treatment, rather than abrupt cessation, appear unsupported by any direct clinical evidence. 36 Given the benefits of domperidone observed in this review, areas relating to dose and duration of treatment that may further improve treatment efficacy represent key areas of future research. Collectively, the evidence supports the use of domperidone at a dose of 10 mg three times daily for 2 weeks in mothers of preterm infants experiencing low milk supply.
Recently, concerns have arisen regarding the increased risk of adverse cardiac effects associated with the use of domperidone in general adult populations, 37 but the relevance of these findings to younger, healthier lactating women is uncertain and has been questioned. [12] [13] [14] Such concerns have led international regulatory agencies such as the European Medicines Agency and Health Canada to recommend caution regarding the use of domperidone. 38, 39 The largest body of evidence regarding the potential cardiac safety of domperidone in lactation comes from a recent Canadian study by Smolina et al. 40 They identified 45 518 women who were dispensed domperidone in the postnatal period, of which 21 cases of ventricular arrhythmia were identified with no deaths. Although the authors concluded that they found a possible association between domperidone exposure and hospitalisation for ventricular arrhythmia (adjusted hazard ratio 1.69; 95% CI 0.48-5.96), all cases occurred among women who had a previous history of ventricular arrhythmia. That is, among 43 683 with no previous history of cardiac arrhythmia who were prescribed domperidone, there was not a single case of ventricular arrhythmia. 40 Notably, according to a previous drug utilisation study undertaken by the same authors, approximately 90% of women included in the study were exposed to doses >30 mg daily. 9 This finding suggest domperidone is associated with a very small risk of cardiac arrhythmia when used in accordance with established prescribing guidelines that contraindicate use in women with a previous history of cardiac arrhythmia. 41 Further supporting evidence can be taken from the study by Asztalos et al. 29 included in this review in which 90 women had an ECG at study entry and at the end of the 4-week study period, with no women having any evidence of QTc prolongation. Lastly, a recent review of two studies using the regulatory agency gold standard for assessment of QT prolongation concluded that domperidone (tested up to 80 mg/day) is not associated with QT prolongation in healthy female volunteers. 42 Based on this evidence, any future RCTs attempting to evaluate the impact of domperidone on cardiac arrhythmias or sudden cardiac death would require a sample size of >100 000 women, which is clearly impractical.
Conclusion
In situations where mothers of preterm infants continue to experience low milk supply despite the use of nonpharmacological strategies, short-term domperidone use results in a modest 88 ml/day increase in expressed breast milk volume. Initiation of domperidone should only occur after careful assessment of the women and implementation of non-pharmacological support such as lactation consultation, increasing frequency of expressing and the use of appropriate mechanical expression devices. Despite concerns regarding the potential of prolonged QTc syndrome and sudden cardiac death, the risks associated with domperidone use among healthy lactating women with no history of cardiac arrhythmia appear small.
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